ibandronate sodium hydrate / Generic mfg. - LARVOL DELTA

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Khyber Medical University Peshawar

New trial • Osteoporosis • Rheumatology

Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States (ACR Convergence 2025) - "Anabolic therapy (AT), the RANKL inhibitor denosumab (Dmab), and intravenous zoledronic acid (ZOL) are recommended as initial therapy for patients at very high risk (VHR) for fracture...OP medications included oral bisphosphonates (BPs; alendronate, risedronate, ibandronate), Dmab, ZOL, and AT (romosozumab, parathyroid hormone analogues [teriparatide, abaloparatide])... More than 1/3 of untreated PMO women are at VHR for fracture and eligible for ATs, Dmab, or ZOL in accordance with treatment guidelines. Among treated VHR PMO women, over half were treated with oral BP in contradiction with current treatment guidelines. Only a small percentage were treated with ATs, which clinical studies have shown are the most effective initial therapy for PMO women at VHR for fracture."

Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rare Diseases • Rheumatology

Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries. (PubMed, Osteoporos Int) - "Many patients stopping denosumab do not receive follow-on therapy. Proactive follow-up and strong clinical communication would reduce treatment gaps and prompt follow-on therapy after discontinuation."

Journal • Medicare • Reimbursement • US reimbursement • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network. (PubMed, Bone) - "This study used real-world data from the TriNetX platform to evaluate the risk of MRONJ associated with various anti-osteoporosis medications, excluding combination therapies for clarity. Our findings indicate that among the commonly used parenteral anti-resorptive agents, denosumab has been associated with the highest risk of MRONJ, followed by zoledronic acid, with ibandronate showing the lowest risk."

Journal • Real-world evidence • Retrospective data • Oncology • Osteoporosis • Rheumatology

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion. (PubMed, World Neurosurg) - "Osteoporosis is linked to higher reoperation and medical complications following lumbar fusion. Although osteoporosis medications did not significantly alter reoperation risk, their potential role in perioperative optimization requires further investigation."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Nephrology • Orthopedics • Osteoporosis • Pneumonia • Respiratory Diseases • Rheumatology • Thrombosis

EFFICACY AND SAFETY OF ORAL IBANDRONATE IN PATIENTS OF LIVER CIRRHOSIS WITH HEPATIC OSTEODYSTROPHY: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL[NCT06022237] (AASLD 2025) - P=N/A | "Oral Ibandronate improves BMD both at lumbar spine and femur neck significantly better than placebo. It is well tolerated and produces minimal adverse events. It should be recommended for Child A and B cirrhosis patients with osteodystrophy"

Clinical • Cholestasis • Dyspepsia • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Liver Cirrhosis • Musculoskeletal Diseases • Orthopedics • Osteoporosis

Osseointegration of Nitrogen-Containing Bisphosphonate Coatings on Dental Implants: An Experimental Pilot Study. (PubMed, J Biomed Mater Res B Appl Biomater) - "Zoledronate-coated implants exhibited enhanced early mechanical stability compared to ibandronate/pamidronate-coated implants. However, this advantage was eradicated after 28 days, suggesting that the early anabolic effect of zoledronate may be time-limited."

Journal

Clinical and economic research of bone modifiers as adjuvant therapy for early breast cancer: A systematic literature review. (PubMed, Breast) - "Many unresolved issues remain regarding bone modifiers in EBC adjuvant therapy. Insufficient clinical and economic evidence precludes drawing comprehensive conclusions at present. Future studies need to provide higher-quality evidence to deepen our understanding of adjuvant therapy with bone modifiers."

Journal • Review • Breast Cancer • Musculoskeletal Diseases • Oncology • Solid Tumor

Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021. (PubMed, Orthopedics) - "In line with national guidelines, claims for NSAIDs are increasing and claims for opioid pain medications and AOMs are decreasing. Claims for outpatient antibiotics are increasing, which is of significant concern, given renewed focus on antibiotic stewardship."

Journal • Medicare • Reimbursement • Review • US reimbursement • Orthopedics • Pain

Promising efficacy of nitrogen-containing bisphosphonates against the infection of Cryptosporidium spp. (PubMed, Int J Parasitol Drugs Drug Resist) - "This study determined the anti-Cryptosporidium effect of three nitrogen-containing bisphosphonates risedronate, ibandronate, and zoledronate through both in vitro and in vivo experiments. was assessed. Risedronate show promising effect for further development of new anticryptosporidial drugs."

Journal • Infectious Disease • IL2 • IL4 • TNFA

Efficacy and safety of technetium [99Tc] methylenediphosphonate in the treatment of osteoporotic vertebral compression fractures: a prospective, randomized, controlled, multicenter study (ChiCTR) - P=N/A | N=160 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University

New trial • Musculoskeletal Diseases • Orthopedics

Ibandronic Acid Induced Orbital Inflammation and Concurrent Anterior Uveitis - A Rare Presentation. (PubMed, Rom J Ophthalmol) - "To report the first case of orbital inflammation with concurrent anterior uveitis induced by oral Ibandronate, a bisphosphonate used for osteoporosis and other bone disorders...After discontinuing the drug, the patient was treated with intravenous methylprednisolone, leading to significant improvement in ocular symptoms...Early detection and timely discontinuation of the drug can avoid sight-threatening complications. This case underscores the importance of early recognition and prompt management of ocular complications, particularly as the use of bisphosphonates continues to increase."

Journal • Cardiovascular • Diabetes • Hypertension • Immune Modulation • Immunology • Inflammation • Metabolic Disorders • Musculoskeletal Diseases • Ocular Inflammation • Oncology • Ophthalmology • Orthopedics • Osteoporosis • Pain • Rheumatology • Uveitis

Systemic Mastocytosis Presenting as Recurrent Vertebral Compression Fractures (ENDO 2025) - "At this time he started ibandronate for one year before transitioning to risendronate for a total treatment duration of 2 years before discontinuation for unclear reasons...The patient since completed a course of teriparatide and most recently started treatment with zoledronic acid. Systemic mastocytosis is a rare but underrecognized cause of secondary osteoporosis and fragility fractures. Screening with serum tryptase should be considered in an adult with osteoporosis and pathologic bone fractures if no other risk factors for osteoporosis are identified or if other complementary features are present."

Back Pain • Eosinophilia • Fatigue • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoporosis • Pain • Rheumatology

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Kelly Fitzgerald, MD

Checkpoint inhibition • New P2 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Atypical Femoral Fracture Following Long-Term Bisphosphonate Therapy: An Uncommon Complication of a Common Treatment. (PubMed, Cureus) - "After a decade of ibandronate use for osteoporosis, she sustained a subtrochanteric femoral fracture following minimal trauma...Laboratory evaluation revealed no evidence of secondary bone disease. This case highlights the importance of monitoring patients on long-term bisphosphonates and considering drug holidays to minimize the risk of atypical fractures."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database. (PubMed, Sci Rep) - "All studied bisphosphonates except ibandronate sodium and clodronate disodium were correlated with the reporting frequency of cardiac arrhythmia (HLGT), with ROR ranging from 1.28 with pamidronate disodium to 11.08 with etidronate disodium. Bisphosphonates use is associated with adverse cardiac arrhythmias, with the exception of ibandronate sodium and clodronate disodium. Our data support differential effects of BPs on cardiac arrhythmias."

Journal • Cardiovascular

Systemic or local administration of bisphosphonate and the orthodontic tooth movement in animals: a systematic review. (PubMed, Eur J Orthod) - "Local or systemic application of bisphosphonate can alter the bone remodeling cycle, affecting osteoclast activity and, consequently, orthodontic tooth movement. So, they could be applied to give a high degree of anchorage to limit adverse movement. However, longer-term research is needed to evaluate potential side effects from bisphosphonate use during orthodontic treatment."

Journal • Review • Osteoporosis

ANTIRESORPTIVE TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: DO ORALLY ADMINISTERED DRUGS WORK (EULAR 2025) - "Antiresorptive therapies included alendronate (n=17), zoledronate (n=7), denosumab (n=11), risedronate (n=2), and ibandronate (n=1). Antiresorptive therapy appears effective and safe in patients with SSc. Subgroup analysis suggests that parenteral therapies may be more effective, with denosumab showing the most consistent improvements in axial BMD. Notably, both oral and parenteral antiresorptive drugs were well-tolerated, as no adverse events were observed."

Clinical • Gastrointestinal Disorder • Immunology • Osteoporosis • Rheumatology • Scleroderma • Systemic Sclerosis

A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "A total of 36 (16.7%) patients were exposed to bisphosphonate therapy including Alendronate(17), Ibandronate(4), Risedronate(6), Zoledronate(9), and 13, 3, 4, and 8 patients were detected with low BMD, respectively. This is the first study evaluating the prevalence of low BMD in young patients with SLE in India. Low BMD was observed in 28.12% of patients. In SLE, nephritis and higher cumulative dose of glucocorticoids may contribute to elevated fracture risk."

Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Rheumatology • Systemic Lupus Erythematosus

Long-term cardiovascular and skeletal effects of bisphosphonate treatment in the first year after kidney transplantation; a 13-year prospective follow-up of a randomized controlled study of ibandronate vs placebo (ERA 2025) - "There was no difference in the incidence of cardiovascular events between the ibandronate and placebo group. BMD was reasonably well preserved 13 years after transplantation irrespective of treatment, with even a small protective effect of the 1-year ibandronate study intervention."

Clinical • Atrial Fibrillation • Cardiovascular • CNS Disorders • Musculoskeletal Diseases • Orthopedics • Transplantation • Vascular Neurology

Comparative efficacy and safety of bisphosphonates and other bone-modifying agents in patients with bone metastases from lung cancer: A systematic review and Bayesian network meta-analysis. (ASCO 2025) - "Pamidronate was identified as the most effective BMA for improving survival, while Denosumab demonstrated a strong effect in reducing skeletal-related events but was associated with a higher risk of adverse events. Zoledronic Acid and Ibandronate showed moderate efficacy with favorable safety profiles. These findings provide evidence-based guidance for selecting optimal BMAs and supporting clinical decision-making in this patient population."

Retrospective data • Review • Lung Cancer • Oncology • Pain • Solid Tumor

Efficacy and safety of bisphosphonates therapy for patients diagnosed with multiple myeloma: A comprehensive Bayesian network meta-analysis. (ASCO 2025) - "Bisphosphonates, including zoledronic acid, pamidronate, and ibandronate, are widely used to manage these bone-related events... For OS, etidronate ranked highest (RR = 1.22, 95% CrI: 0.22–2.54, SUCRA: 74.62%), followed by control (SUCRA: 69.38%), pamidronate (RR = 0.80, 95% CrI: 0.37–1.38, SUCRA: 41.23%), and clodronate (RR = 0.78, 95% CrI: 0.28–1.38, SUCRA: 38.04%), with zoledronate ranking the lowest (SUCRA: 10.47%)... This analysis highlights etidronate as the most effective for OS, pamidronate for PFS and vertebral fractures, and zoledronate for SREs. These findings emphasize the value of bisphosphonates in managing myeloma bone disease, providing evidence to guide individualized treatment decisions."

Retrospective data • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics • Pain

Bisphosphonates with high bone-resorption-capacity promote osteonecrosis of the jaw development after tooth extraction in mice. (PubMed, J Bone Miner Metab) - "Administration of BPs with high osteoclastogenesis inhibitory potential, such as zoledronate, increases risk of ONJ development after tooth extraction more than treatment with other agents tested, even at equivalent dosage."

Journal • Preclinical • Osteoporosis • Rheumatology

Meningeal malignant solitary fibrous tumor with multiple recurrence, extracranial extension, cervical lymph node metastases: case report and review of the literature. (PubMed, Discov Oncol) - "We report the first case of extracranial extension and cervical lymph node metastases from meningeal malignant SFT. This finding provides novel insights into the dissemination patterns of intracranial SFT. Surgical resection is the gold standard for the treatment. Postoperative radiotherapy (PORT) whether gross total resection (GTR) or subtotal resection (STR) may be the optimal treatment strategy, but PORT dose < 60 Gy with IMRT or marginal dose < 15 Gy with GKRS may be insufficient. Close and long-term follow-up, especially in the first five years after diagnosis, is essential to manage such patients because of high risk of recurrence and metastasis."

Journal • Brain Cancer • CNS Tumor • Meningioma • Oncology • Solid Tumor • Spindle Cell Sarcoma • CD34 • VIM